TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Feb 22, 2021 13:11 JST
Source:
Eisai
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy
TOKYO, Feb 22, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the 18th Corporate Philanthropy Award (FY 2020) of the Japan Philanthropic Association. The presentation ceremony was held on February 19, 2021 (Friday) at the GakushiKaikan (Chiyoda-ku, Tokyo).
The Corporate Philanthropy Award was founded in 2003 with the aim of commending companies for their activities for social contribution that organically and sustainably utilize their management resources (human resources, know-how, technology, information, etc.) in order to solve social issues, and of passing on a fair, warm and vibrant society to the next generation by broadly disseminating those social contribution activities to society.
The award was presented to Eisai for its corporate philosophy of human health care (hhc) and its activities to realize the hhc philosophy, evaluating "a corporate culture and purposeful activities where employees demonstrate their true value toward the realization of a society in which people can live happily."
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In 2005, Eisai stipulated this philosophy as one of its Articles of Incorporation with the support of its shareholders. As an initiative to embody this hhc philosophy, Eisai recommends all officers and employees of the Eisai Group, including outside directors, to spend 1% of their business hours with patients and to engage in "socialization" to know their emotions. In addition, for developing and emerging countries, Eisai has continuously provided a treatment for lymphatic filariasis, which is one of the neglected tropical disease (NTDs), free of charge to endemic counties through the World Health Organization (WHO). Furthermore, Eisai has adopted the tiered-pricing model for its innovative new drugs, which sets multiple tiered prices according to the patient's income level and the insurance coverage that patients could afford. Thus, we are promoting various efforts to improve access to pharmaceutical products.
Award ceremony (left: Ms. Yoko Takahashi, director, the Japan Philanthropic Association, right: Keigo Kato, executive director, Knowledge Creation Dept., Eisai)
Eisai will make continuous efforts, based on the hhc philosophy, to further contribute to increasing the benefits of patients and their families around the world.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
More Press release >>
Latest Press Release
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST
Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST
Fujitsu recognized with two Microsoft Japan Partner of the Year awards
Nov 26, 2025 18:40 JST
Xforce HEV Model Wins Thailand Car of the Year 2025
Nov 26, 2025 18:00 JST
Mitsubishi Motors Launches the All-New Destinator in the Philippine Market
Nov 25, 2025 14:36 JST
New Corporate Slogan "In step with your future."
Nov 25, 2025 13:51 JST
MHI Receives EPC Contract for Cyclo Olefin Polymer Plant for Zeon Corporation
Nov 25, 2025 13:13 JST
DOCOMO Wins Gold Medal in Kaggle, the World's Largest AI Data Science Competition
Nov 22, 2025 00:39 JST
Fujitsu launches integrated package of core system support services for food distribution industry
Nov 22, 2025 00:04 JST
Special Autumn Event: "Anime Tokyo Station Autumn Festival"
Nov 20, 2025 13:00 JST
ANIME TOKYO STATION ON ROBLOX: New Game "ANIME SKILL TCG" Out Now!
Nov 20, 2025 11:00 JST
DENSO and DELPHY Sign Joint Development Agreement to Accelerate Data-Driven Smart Horticulture
Nov 19, 2025 23:41 JST
NEC Presents the Decarbonization Potential of its CropScope Agricultural Solution at COP30
Nov 19, 2025 23:15 JST
Fujitsu recognized as the only Japan-headquartered company to be an Emerging Leader in Gartner(R) Emerging Market Quadrant for Generative AI Engineering
Nov 19, 2025 22:40 JST
Kingsoft Announces 2025 Third Quarter Results
Nov 19, 2025 17:47 JST
Mazda Begins Demonstration Experiment of Onboard CO2 Capture System
Nov 18, 2025 00:38 JST
Pushing Hydrogen Engine Technology to New Heights in the Super Taikyu Series Final Race
Nov 18, 2025 00:00 JST
Fujitsu launches business creation lab in collaboration with AWS Japan
Nov 17, 2025 23:41 JST
NTT DOCOMO Achieves Successful Outdoor Trial of AI-Driven Wireless Interface Toward 6G
Nov 17, 2025 23:05 JST
Destinator Earns the Highest Rating of Five Stars in 2025 ASEAN NCAP
Nov 17, 2025 22:32 JST
More Latest Release >>